Loading stock data…
MCRB
$6.33+0.05 (+0.80%)
After Hours$6.33+0.00 (+0.00%)· Last close Jun 9
Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Seres Therapeutics, Inc. in the Healthcare sector is trading at $6.33 with a market capitalization of $69M. Wall Street consensus targets $22.00 (1 analysts), implying a +247.6% move over the next 12 months. The stock is currently near its 52-week low of $6.01, remaining 53.2% below its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +247.6% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 32) — potential for technical mean-reversion
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$6.33
Potential Downside
0%
Whystock Fair Value$6.33
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus1 analysts
Mean target$22.00+247.6%
Range$22.00 – $22.00
Fundamentals
Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize GI pathogens, enhance GI epithelial barrier integr...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$69.43M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.12
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-176.98%
Volume
Today's trading volume
82,055
Recent News
Seres Therapeutics: Q4 Earnings Snapshot
CAMBRIDGE, Mass. AP) — Seres Therapeutics Inc. MCRB) on Thursday reported a loss of $15.3 million in its fourth quarter.
Sector Update: Health Care Stocks Rise Late Afternoon
Health care stocks were higher late Thursday afternoon, with the NYSE Health Care Index adding 0.8%
Seres to lay off staff, pause top program in latest reboot
The microbiome specialist, which for years has struggled to stay afloat, is cutting its staff by 30% and focusing resources on earlier, immunology-focused research.
3 Beaten-Down Biotech Stocks to Buy for a 2026 Turnaround
Beaten-down biotech stocks like ALT, IBRX and MCRB are eyeing a 2026 rebound as FDA alignment, pipeline progress and approvals fuel optimism.
All You Need to Know About Seres Therapeutics (MCRB) Rating Upgrade to Buy
Seres Therapeutics (MCRB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).